poisar

Stocks · News reference

Actuate Therapeutics Presents Preclinical Data for Elraglusib in Melanoma Models

Fiscal.ai

Actuate Therapeutics announced new preclinical data demonstrating the antitumor and immune activation activity of its oral elraglusib tablet in advanced melanoma models at the ENA 2026 symposium.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)

    Filed: 2026-10-30 AccNo: 0001683168-26-008193 Size: 207 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing